Highly Immunogenic and Totally Synthetic Lipopeptides as
A n attractive option for contraception in man and animals is the use of immunocontraceptive vaccines. The gametes and endocrine hormones that are involved in reproductive function provide a variety of target Ags which have been studied with a view to controlling reproduction through vaccination (1) . Luteinizing hormone-releasing hormone (LHRH), 3 also known as gonadotropin releasing hormone, has the amino acid sequence EHWSYGLRPG and is secreted by the hypothalamus. The hormone enters the portal system and acts on the anterior pituitary, causing the release of follicle stimulating hormone and luteinizing hormone, thereby initiating a cascade of events leading to the control of gametogenesis. Abs directed against LHRH neutralize the hormone's activity, inhibiting the reproductive process and causing reproductive sterility (2, 3) .
Use of LHRH-based vaccines in humans as an immunocontraceptive, although theoretically possible, is unlikely, because profound behavioral modification can occur as a consequence of inhibiting the production of testosterone in males. However, a very active area of research is the use of LHRH-based vaccines in the control of hormone-dependent cancers, including breast (4) and prostate cancers (5, 6) . Because the sequence of LHRH is conserved in all mammals, LHRH-based immunocontraceptives are candidates for use in the companion animal and livestock arenas. Here the concerns of behavioral modification are not of such overriding importance and the use of immunocontraception as an alternative to surgical castration has attracted a great deal of attention (5, (7) (8) (9) (10) .
Although the peptide nature of the hormone makes it an obvious candidate for epitope-based vaccine design, the major problem of poor immunogenicity in the absence of an adjuvant confronts this as it does all peptide-based vaccine candidates. Of the many adjuvants currently available, many are too toxic for use in humans and animals or are ineffective. However, lipids and lipopeptides have been shown to be capable of adjuvanting otherwise weak immunogens (11) (12) (13) (14) (15) and show none of the harmful side effects of other adjuvant formulations. In lipopeptide constructs, a lipid moiety with known adjuvanticity can be covalently coupled to peptide to generate a fully synthetic self-adjuvanting and potentially safe vaccine (16 -19) . There have been a number of successful applications of lipopeptides as immunogens to generate Ab and cellular responses (12, 17, 20) , and several different lipids have been used for these purposes. Tripalmitoyl-S-glyceryl cysteine (Pam3Cys) is a synthetic version of the N-terminal moiety of Braun's lipoprotein that spans the inner and outer membranes of Gram-negative bacteria and has been shown to be capable of stimulating virus-specific CTL responses against influenza virus-infected cells (21) and to elicit protective Abs against foot-and-mouth disease (17) when coupled to the appropriate synthetic epitopes. Recently dipalmitoyl-S-glyceryl cysteine (Pam2Cys), an analog of Pam3Cys, has been synthesized (22) and been shown to correspond to the lipid moiety of macrophage-activating lipopeptide 2 isolated from myoplasma that lack cell walls (23) (24) (25) . In contrast to Pam3Cys, Pam2Cys has only two ester-bound palmitic acids and a free amino group, which leads to improved water solubility of Pam2Cys-peptide constructs compared with Pam3Cys-peptide constructs. It has also been reported that Pam2Cys is a more potent stimulator of splenocytes (22) and macrophages (24, 25) than is Pam3Cys. The structural similarity of Pam2Cys to Pam3Cys and its enhanced macrophage-activating properties, as well as its less hydrophobic nature, indicate that Pam2Cys could also be used as a self-adjuvanting moiety.
In this study, we describe the synthesis of Pam3Cys-and Pam2Cys-peptide constructs based on LHRH and report on their immunogenicity and ability to sterilize female mice when inoculated in the absence of additional adjuvants. These lipopeptides consist of an epitope for CD4 ϩ T cells and the LHRH sequence, which contains one or more epitopes for B cells. Because the LHRH sequence contains no T cell epitopes, the CD4 ϩ T cell epitope GALNNRFQIKGVELKS from the L chain of influenza virus hemagglutinin (26) was incorporated in the construct to provide T cell help. In a previous publication from this laboratory, it was shown that a peptide composed of these two epitopes assembled as a colinear tandem construct was a potent immunogen and able to induce reproductive sterility in female mice when inoculated in CFA (27) . In the present study, either Pam3Cys or Pam2Cys was attached to the peptide-based vaccine to allow delivery in the absence of additional adjuvant. The lipid-containing groups were attached at two different positions within the peptide to produce linear and branched configurations of lipopeptide. The immunogenic properties of these vaccines were determined by examining the titer and isotype of anti-LHRH Ab, and the biological effects were determined by measuring any influence on the reproductive capabilities of vaccinated mice. 
Materials and Methods

Chemicals
Synthesis of Pam3Cys and Pam2Cys
Pam3Cys was prepared according to the method described by Wiesmuller et al. (28) and modified by Zeng et al. (29) . The synthesis of Pam2Cys was adapted from previously described methods (30, 31) ; specifically, 3-bromo-propan-1,2-diol was used instead of 3-chloro-propan-1,2-diol, and centrifugation, not filtration, was used to recover the product.
Peptide synthesis
The general procedure used in this laboratory for the synthesis of peptides has been described previously (32) . To enable lipid attachment between the CD4 ϩ T cell epitope and LHRH, F-moc-lysine(Mtt)-OH was inserted at a point between the two epitopes in the approximate center of the resinbound peptide. Following completion of peptide synthesis, the Mtt group was removed by continual flow washing with 1% TFA in DCM over a period of 30 -45 min.
Pam3Cys or Pam2Cys was then coupled to the exposed ⑀-amino group according to the procedure described previously (29) . Briefly, a 2-fold excess of Pam3Cys or Pam2Cys, OЈbenzotriazole-N,N,NЈ,NЈ-tetramethyluronium-tetrafluoroborate, and 1-hydroxybenzotriazole was dissolved in DCM, and a 3-fold excess of diisopropylethylamine was added. This solution was then added to the resin-bound peptide to generate lipopeptide. Monitoring the reaction by analytical reversed phase (RP)-HPLC, we found that quantitative palmitoylation was achieved after 16 h.
All resin-bound peptide constructs were cleaved from the solid-phase support with reagent B (88% TFA, 5% phenol, 2% triisopropylsilane, and 5% water) for 2 h, and purified by RP chromatography as described previously (33) . Analytical RP-HPLC was conducted using a Vydac C4 column (4.6 ϫ 300 mm; Edwards Instruments, New South Wales, Australia) installed in a Waters (Box Hill, Victoria, Australia) HPLC system and developed at a flow rate of 1 ml/min using 0.1% TFA in H 2 O and 0.1% TFA in CH 3 CN as the limit solvent. All products presented as a single major peak on analytical RP-HPLC and had the expected mass when analyzed by matrix-assisted laser desorption ionization-time of flight mass spectrometry on a Bruker BIFLEX instrument (Bruker Daltonics, Bremen, Germany) equipped with delayed ion extraction. The final quantitation of the immunogens was done by measuring the absorption at 280 nm, exploiting the presence of a tryptophan and a tyrosine residue in the peptide constructs (molar extinction coefficient of 6.6 ϫ 10 3 ). Two serine residues are present between the protein and lipid portion of Braun's lipoprotein from which Pam3Cys is derived (28) . Furthermore, the presence of serine between the lipid and peptide moieties of Pam3Cys-containing lipopeptides has been said to improve immunogenicity (34) . Therefore, we also investigated the effect of serine by incorporating two residues between the peptide and lipid moieties of the Pam2Cys-containing peptide constructs. This was simply done by sequential addition of two serine residues to the peptide before covalent attachment of the lipid moiety.
A schematic diagram of the peptides and lipopeptides used in this study is shown in Fig. 1 and a summary of their characteristics, conducted by analytical RP-HPLC and mass spectrometry, is presented in Table I .
Immunization protocols
Groups of five female BALB/c mice, 6 -8 wk old, were inoculated at day 0 and again on day 28. For s.c. inoculations (100 l volume per dose), lipopeptide constructs were prepared in saline and nonlipidated peptides formulated as an emulsion in an equal volume of CFA for the primary injection or IFA for the secondary inoculation. For intranasal (i.n.) inoculations, 50 l of peptide in saline were applied to the nares of mice anesthetized with penthrane for inhalation. Sera were prepared from blood taken at 4 wk after the primary inoculation and 2 wk after the secondary inoculation.
ELISAs
ELISAs were conducted on serum samples as described previously (27) using LHRH as the coating Ag. The titers of Ab are expressed as the reciprocal of the highest dilution of serum to achieve an OD of 0.2, which represents approximately five times the background binding in the absence of Ab. The isotype of Abs specific for LHRH was determined using rabbit antisera directed against mouse IgM, IgG1, IgG2a, IgG2b, IgG3, or IgA (ICN Pharmaceuticals, Costa Mesa, CA) as previously described (27) .
Fertility studies
After being inoculated with peptide immunogen and following exposure to male mice, female mice were tested for their ability to drop litters. A group of mice immunized with saline in CFA was used as a control. A male mouse was introduced into a cage in which two or three female mice were kept, and male mice were rotated between each cage to expose each group of female mice to every male. Males and females were kept together for a total of 3 wk, at the end of which the males were removed and the females kept under observation.
Dendritic cell (DC) culture
DC were cultured in medium based on complete IMDM. This consisted of IMDM containing 25 mM HEPES and without ␣-thioglycerol or L-glutamine (JRH Bioscience, Lenexa, KS), supplemented with 10% (v/v) heatinactivated (56°C, 30 min) FCS (CSL, Victoria, Australia), gentamicin (24 g/ml), glutamine (2 mM), sodium pyruvate (2 mM), penicillin (100 IU/ ml), streptomycin (180 g/ml), and 2-ME (0.1 mM). For DC generation, complete IMDM was further supplemented with 30% supernatant from cultured NIH/3T3 cells and 5% GM-CSF in the form of a supernatant from Ag8653 cells transfected with the GM-CSF gene (DC medium).
The culture method for immature DC was adapted from Winzler et al. (35) . Spleen cells from a BALB/c mouse were seeded at 1.5 ϫ 10 6 cells per 55-mm dish (Techno-Plas, South Australia, Australia) in 3 ml of DC medium and incubated at 37°C with 5% CO 2 . All the equipment used for culturing was pyrogen free. The medium was changed every 4 days, and all cells were returned to the dish. On day 12, both suspended and weakly adherent cells were collected by forcefully pipetting and then aspirating the medium. The procedure was repeated with 2 ml of PBS. The remaining strongly adherent cells were discarded. The collected cells were pelleted by centrifugation and reseeded into a new dish. Cells were subsequently maintained on a 4-day alternating cycle of medium change and passage. After 1 mo of continuous culturing, the floating and semiadherent cells took on the appearance and staining characteristics of immature DC and are referred to as D1 cells. Under these passage conditions, the majority of cultured D1 cells maintain an immature phenotype characterized by an intermediate expression level of cell surface MHC class II molecules.
Flow cytometric analysis of D1 cells
D1 cells (8 ϫ 10
4 cells per sample) were seeded in a new petri dish with 1 ml of DC medium and incubated with 0.0045 nmol lipopeptide, dissolved in complete IMDM. LPS purified from Escherichia coli serotype O111:B4 (Difco, Detroit, MI; a kind gift from Dr. E. M. Anders, Department of Microbiology and Immunology, University of Melbourne) was used at 5 g/ml as a positive control for DC maturation. After overnight incubation, the cells were harvested and washed once with PBS with 1% FCS. To prevent nonspecific binding to Fc␥RII/III, the cells were preincubated with 20 l of normal mouse serum for 5 min at room temperature. The cells were then exposed to FITC-conjugated mAb 14-4-4S (IgG2a, anti-I-E k,d ) (36) for 30 min on ice. mAb 36/1 (37) specific for the hemagglutinin of influenza virus was used as an isotype control. All Abs were used at 2.5 g/ml. The samples were washed once with PBS containing 1% FCS and fixed with PBS containing 4% paraformaldehyde on ice for 15 min. Flow cytometry analysis was performed using a FACSort (BD Biosciences, San Jose, CA), and the data were analyzed using FlowJo software (Tree Star, San Carlos, CA)
Results
Solubility properties of the lipopeptides
Visual inspection (Fig. 1) of the different lipopeptide preparations showed that they differed markedly in their solubilities. Better solubility was most evident in those cases where lipid was attached between the two epitopes at the approximate center of the mole- , which was simply admixed with Pam3Cys-Ser-(Lys) 4 in the ratio 1:1 or 1:5, did not elicit significant levels of anti-LHRH Ab, a finding that contrasts with other results reported using Pam3Cys-Ser-(Lys) 4 (38) as an externally added adjuvant.
Ab titers and the fertility status of animals were determined following the second dose of vaccine. The results (Table II) 
Pam2Cys is a more potent adjuvant than Pam3Cys
The results presented in Fig. 2 and Table II a RP chromatography was carried out on Vydac C4 column (4.6 ϫ 300 mm) installed in a Waters HPLC system and developed at a flow rate of 1 ml/min using 0.1% TFA in H 2 O and 0.1% TFA in CH 3 CN as the limit solvent.
b Mass spectrometric measurements were carried out using a Bruker Biflex matrix-assisted laser desorption ionization-time of flight instrument equipped with delayed ion extraction. Analysis was carried out in the linear mode.
Pam3Cys-Ser-Ser-[T]-[B], and Pam2Cys-Ser-Ser-[T]-[B]
. The results presented in Fig. 2 and Table II (Table III) 
i.n. immunization with Pam2Cys-peptide induces strong specific systemic Ab responses
It has been reported previously that immunization with Pam3Cys-containing peptides by the mucosal (oral or i.n.) route induces strong mucosal and/or systemic immune responses (33, 39, 40) . In Following two i.n. inoculations, each of the vaccines induced similar titers of serum anti-LHRH Abs, which were slightly lower than those induced following s.c. inoculation (Table IV) A comparison of the longevity of the responses induced by the two constructs when administered by the two different routes is also shown in Table IV . Twenty-six weeks following the second dose of vaccine, the levels of Ab in all mice had dropped below those observed 2 wk after the second dose. However, the decrease in anti-LHRH Ab in the group that received [T]-Lys(Pam2Cys-Ser-Ser)-[B] s.c. was much less apparent, again indicating the immunological superiority of the configuration in which Pam2Cys-Ser-Ser is attached at the center of the molecule.
We also determined the titers of individual Ab isotypes that were directed toward LHRH and obtained from animals following two s.c. or i.n. doses of the soluble lipopeptide [T]-Lys(Pam2Cys-Ser-Ser)- [B] (Fig. 3) . i.n. inoculation appeared to induce higher levels of IgG3, IgG2b, and possibly IgM than did s.c. inoculation, even though the amount of total Ig induced by i.n. inoculation was less.
Exposure of DC to peptides and lipopeptides induces different levels of cell surface MHC class II molecules
The priming of naive CD4 ϩ T cells in secondary lymphoid organs by DC is preceded by maturation of DC upon exposure to Ag. This maturation is characterized by up-regulation of MHC products and costimulatory molecules on the DC surface. Therefore, we determined whether the various peptides and lipopeptides could differentially activate DC in an attempt to explain the different immunogenic properties of these vaccine candidates. The results of experiments (Fig. 4) in which a line of immature DC, D1 cells, were exposed to peptides, stained for surface expression of MHC 4 (1:5 admixture)
peptides [T]-[B] and [T]-Lys-[B]
were each administered in CFA, and saline was also administered in CFA as a control. All other peptide constructs were administered in saline. The dose of each peptide was 20 nmol, and all inocula were administered s.c.
b Titers represent the geometric means of groups of five female BALB/c mice. displayed intermediate levels of activation. The nonlipidated peptide was unable to induce maturation of D1 cells at a rate greater than 26%, which is the rate that occurs spontaneously in culture. The ability of the lipopeptides to induce the maturation of D1 cells was concentration dependent (data not shown). The relative abilities of these lipopeptides to induce maturation of D1 cells directly reflected their ability to induce Ab, providing a possible mechanism for differences in immunogenicity.
Discussion
Previous reports have shown that, when coupled covalently to a peptide, Pam3Cys endows self-adjuvanting properties, enabling humoral (17, 38) and cellular responses (21, 38) to be elicited. Pam2Cys, an analog of Pam3Cys that has been isolated from mycoplasma, has also been reported to be capable of activating macrophages and splenocytes (22, 24, 25) . The ability to chemically synthesize vaccines provides opportunities to incorporate immunostimulatory lipids at various positions within immunogens, allowing the final structure to be tuned to give the best or most appropriate immune response. In this study, we describe the assembly of a variety of lipopeptide immunogens composed of a CD4 ϩ T cell epitope, the self-peptide LHRH, which includes one or more B cell epitopes, and Pam3Cys or Pam2Cys.
We found that the solubility of the resulting vaccine was greatly improved by placing lipids in the approximate center of the peptide immunogen between the T cell epitope and LHRH instead of at the more usual position at the N terminus. A clear solution in saline at the concentration required for inoculation could easily be obtained with these branched structures. In contrast, the immunogens in which the lipid was coupled at the N terminus were less soluble, giving a cloudy or opalescent solution in saline. Investigation of the Ab responses and subsequent fertility trials indicated that the water-soluble lipopeptides induced higher Ab titers 4 wk after the primary inoculation and were also more efficient in preventing pregnancy than were the less soluble lipopeptides where lipid was attached to the N terminus. A water-soluble self-adjuvanting vaccine has clear advantages over partially soluble or insoluble material, allowing for simplification of the manufacturing process and more accurate metering of dose.
Investigations into the effects of varying the lipopeptide dose indicated that Pam2Cys-containing lipopeptides are better immunogens than are Pam3Cys-containing peptides. This may correlate with the finding that Pam2Cys is a more potent macrophage and splenocyte stimulator than Pam3Cys (22, 24, 25) . In the present study, we found that insertion of two serine residues between the lipid moiety and the peptide sequence increased the potency of the resulting Pam2Cys-containing immunogens. Two serine residues are present in the original Braun's lipoprotein sequence found in bacterial cell walls from which Pam3Cys is derived (28) and were reported in early publications (17, 34) to be important for activity of Pam3Cys-containing peptide constructs. Later studies also demonstrated that insertion of Ser-D-Ser instead of Ser-Ser markedly decreased immunogenicity (41) . However, serine residues are absent in naturally occurring Pam2Cys-containing structures including macrophage-activating lipopeptide 2 (25) and the splenocytestimulating lipopeptides initially investigated (22) . In this study, where lipid is attached to the N terminus, the two serine residues could be acting either as an inert spacer between the lipid and the peptide sequence or as an extension of the T helper cell epitope and perhaps modulating immunological activity. In those cases where lipid is coupled to the ⑀-amino group of a lysine residue at the center of the molecule, the two serine residues are probably b Fertility experiments were initiated 2 wk after the second dose of vaccine.
acting as a spacer. Experiments where the two serine residues are replaced by an inert spacer such as 6-aminohexanoic acid may resolve the question of whether these serine residues per se are important.
To determine a mechanism for the enhanced immunogenicity of particular lipid-containing constructs, we considered the known ability of Pam3Cys and Pam2Cys to activate macrophages. It is now understood that macrophages can be stimulated by microbial products that bind to cell surface receptors; the signal resulting from this binding event is transmitted via Toll-like receptors and results in the production of pro-inflammatory cytokines and chemokines. These receptors are also present in populations of DC (for review, see Ref. 42 ) and, when engaged, transmit signals for cellular maturation and migration as well as for the production of molecules required for efficient Ag presentation.
The various synthetic lipopeptide vaccines used in this study were found to induce the up-regulation of class II MHC molecules, a marker used to assess DC maturation, on the surface of immature DC. In contrast, the nonlipidated peptide construct was unable to cause maturation of DC, indicating that the lipid moiety is responsible for the effect. Microbial lipopeptides have been similarly shown to activate DC of human origin via an interaction involving Toll-like receptor 2 (43) . In this study, we demonstrate that the hierarchy of lipopeptide-induced maturation of DC reflects the hierarchy of immunogenicity exhibited by the peptide constructs, implying that the ability of the vaccine to interact with and induce maturation of DC leads to a better immune response, possibly by increasing the efficiency of CD4 ϩ T cell priming by DC that have been signaled to mature and migrate to the draining lymph node.
The lipopeptides can trigger an immune response in the absence of additional adjuvant and can therefore be delivered by nonparenteral routes. Therefore, we investigated the Ab response following i.n. inoculation of Pam2Cys-containing peptides. Previous reports have shown that oral or i.n. inoculation of Pam3Cys-peptides induces strong mucosal and/or systemic responses (33, 39, 40 ) vaccines suggested that there may be a correlation between infertility and primary Ab response. However, we have previously shown (27) that litters are still produced by animals in which primary Ab titers are similar to the secondary Ab titers of infertile animals, indicating that it is not a simple matter of Ab titer determining fertility or otherwise. Furthermore, the avidities of Abs generated in these two situations are comparable (27) . These observations suggest that the success or otherwise of antifertility vaccines based on LHRH is related to effects other than quantitative (titer) or qualitative (affinity) properties of the Ab; contributing factors could include the length of time for which the endocrine system is bathed in Ab. For these reasons, it seems to be advantageous to use those antifertility vaccines that not only induce high Ab titers but induce high Ab titers as quickly as possible. Of course, this property applies to most vaccines.
The efficacy of the antifertility vaccines was also examined following i.n. administration. i. Taken together, the measurements of Ab titers and the results of the fertility trials demonstrate that placement of self-adjuvanting lipid moieties between the B cell epitope and the T helper epitope, at the approximate center of a totally synthetic peptide vaccine, increases the solubility and the immunogenicity of the vaccine. This improved immunogenicity can be further improved by the introduction of two serine residues between the lipid and the peptide portion of these branched peptide vaccines. The finding that incorporation of lipid, self-adjuvanting moieties into different positions of peptide-based vaccines profoundly alters physical, immunogenic, and biological properties provides another strategy for successful vaccine design.
